Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity

Biochemical and Biophysical Research Communications

Volumn 384, Issue 2, 2009, Pages 255-258

  Reichling, Laurie J ^a   Riddle, Steven M ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

G2019S; I2020T; Kinase inhibitor; LRRK2; Parkinson's disease; Sunitinib; Sutent

Indexed keywords

ADENOSINE TRIPHOSPHATE; JANUS KINASE 3; K 252A; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE INHIBITOR; STAUROSPORINE; SUNITINIB;

ARTICLE; BINDING ASSAY; CELL LEVEL; ENZYMATIC ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; LEUCINE RICH REPEAT KINASE 2 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; WILD TYPE;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 65549108001     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.098     Document Type: Article

References (15)

1. Mayeux R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26 (2003) 81-104
2. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., and Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29 (2006) 286-293
3. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., and Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23 (2006) 329-341
4. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., and Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405 (2007) 307-317
5. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102 (2005) 16842-16847
6. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007) 223-232
7. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., and Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52 (2006) 587-593
8. Anand V.S., Reichling L.J., Lipinski K., Stochaj W., Duan W., Kelleher K., Pungaliya P., Brown E.L., Reinhart P.H., Somberg R., Hirst W.D., Riddle S.M., and Braithwaite S.P. Investigation of leucine-rich repeat kinase 2. FEBS J. (2008)
9. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006) 1231-1233
10. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
11. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
12. Gribble F.M., Loussouarn G., Tucker S.J., Zhao C., Nichols C.G., and Ashcroft F.M. A novel method for measurement of submembrane ATP concentration. J. Biol. Chem. 275 (2000) 30046-30049
13. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140 (1994) 1-22
14. C.S. Lebakken, S.M. Riddle, U. Singh, W.J. Frazee, H.C. Eliason, Y. Gao, L.J. Reichling, B.D. Marks, K.W. Vogel, Development and applications of a broad-coverage, TR-FRET based kinase binding assay platform, J. Biomol. Screen, in press.
15. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., and Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105 (2008) 2070-2075